Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $106 to $129.
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $106 to $129.